FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial. PMID 41511419 · Gastroenterology · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care. PMID 41502912 · Immunooncol Technol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease. PMID 41500915 · J Prev Alzheimers Dis · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Indocyanine green fluorescence-guided proximal margin identification in laparoscopic distal gastrectomy: a randomized clinical trial. PMID 41489800 · Gastric Cancer · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Aurantii Fructus Immaturus Flavonoid Tablets in Patients with Functional Dyspepsia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial. PMID 41489782 · Chin J Integr Med · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial. PMID 41483190 · Naunyn Schmiedebergs Arch Pharmacol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review. PMID 41482478 · Br J Haematol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials. PMID 41478774 · Eur Urol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| SARS-CoV-2 resistance analyses from the Phase 3 OAKTREE study of obeldesivir in low-risk nonhospitalized participants with COVID-19. PMID 41475511 · Antiviral Res · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder. PMID 41442783 · Sleep Med · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Progression-free survival is strongly associated with overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era. PMID 41429401 · J Cancer Policy · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD). PMID 41423505 · Br J Cancer · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Innovative oncology trial designs: Time to act - A review with recommendations of the Cancer Drug Development Forum. PMID 41423143 · J Cancer Policy · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial. PMID 41422947 · J Thromb Haemost · 2026-Mar The study is a reanalysis of a randomized trial in cancer patients using a 'win ratio' composite endpoint, which does not meet the required time-to-event efficacy endpoint criteria (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Additionally, the trial phase is not explicitly confirmed as Phase III or IIIb. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial. PMID 41417560 · Diabetes Obes Metab · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer. PMID 41416818 · Cancer Sci · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. PMID 41390254 · Clin Colorectal Cancer · 2026-Mar The record describes a Phase II prospective study (TRAVASTIN) with a randomized component for a secondary comparison. While it reports original OS data, the primary trial phase is not Phase III/IIIb or Phase II/III, which is a required criterion. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A comparative study of the repair of surgical defects of the hypopharynx with the pedicled thoracoacromial artery perforator and supraclavicular artery island flap. PMID 41390242 · Acta Otolaryngol · 2026-Mar The study is a randomized trial in human oncology patients but is ineligible because it lacks a drug intervention and a time-to-event efficacy endpoint, focusing instead on surgical reconstruction outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1-5. PMID 41387317 · Diabetes Obes Metab · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. PMID 41387279 · HIV Med · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| RoLaCaRT-1: pilot randomised phase II study of robotic vs laparoscopic hemicolectomy for right colon cancer. PMID 41372621 · Surg Endosc · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial. PMID 41366610 · Diabetes Obes Metab · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ivor Lewis minimally invasive oesophagectomy versus McKeown approach: short-term benefits and mid-term equivalence in a randomized trial for oesophageal squamous cell carcinoma. PMID 41345532 · Surg Endosc · 2026-Mar The record describes a randomized surgical trial (Ivor Lewis vs McKeown oesophagectomy) for esophageal squamous cell carcinoma. It meets criteria for oncology, human, randomized, time-to-event endpoint (PFS), and original result. However, it fails the key criterion of a drug-containing intervention, as the comparison is between two surgical techniques. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or II/III in the provided metadata (phase3: false). Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Short-Term Nutrition and Exercise Trial Program for Patients with Esophageal Cancer: A Randomized Clinical Trial: Thoracic Oncology. PMID 41335173 · Ann Surg Oncol · 2026-Mar The study is an original, randomized, oncology trial in humans but does not meet key eligibility criteria: it lacks a drug-containing intervention (intervention is nutrition and exercise prehabilitation), lacks a time-to-event efficacy endpoint (primary outcome is a continuous physiological measure, not OS/PFS/DFS/etc.), and does not appear to be a Phase III/IIIb or Phase II/III drug efficacy trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robustness of randomized controlled trial evidence for SGLT2 inhibitors in heart failure with preserved and mildly reduced ejection fraction. PMID 41314931 · Eur J Intern Med · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Modified Chitosan Medical Membrane on the Inflammation and Recurrence After Primary Pterygium Excision: A Prospective Randomized Clinical Study. PMID 41314274 · Am J Ophthalmol · 2026-Mar The study is a randomized trial with results, but it is not oncology (pterygium excision), does not involve a drug intervention (chitosan membrane is a device/material), and lacks a primary time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial. PMID 41310935 · BJU Int · 2026-Mar Eligibility requires a definitive Phase II/III or Phase III randomized trial with a drug-containing intervention and a primary or key secondary time-to-event efficacy endpoint. This study is randomized and oncology-related but lacks explicit Phase III status, does not involve a systemic drug intervention (it tests nutritional support), and does not report any time-to-event endpoints (OS, PFS, DFS, etc.) or survival analyses (Kaplan-Meier, HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. PMID 41297734 · J Heart Lung Transplant · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer. PMID 41296193 · Oncol Ther · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow-up in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. PMID 41293883 · Histopathology · 2026-Mar The study is an oncology randomized trial with a time-to-event endpoint, but it lacks a drug intervention (it's a screening study) and the trial phase is not specified as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. PMID 41276768 · Ann Surg Oncol · 2026-Mar While the trial is randomized, oncologic, human, includes a drug intervention, and reports time-to-event efficacy endpoints, the abstract and metadata do not explicitly state the trial phase (e.g., Phase II or Phase III). The inclusion criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not present. Therefore, the record is ineligible due to missing phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Repeated-dose behavioral intervention to reduce opioid overdose among overdose survivors with opioid use disorder: A two-site phase III randomized controlled trial. PMID 41261059 · Addiction · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dynamics of early electroencephalographic patterns and epileptic seizures in acute intracerebral hemorrhage: A prospective controlled study. PMID 41250972 · Epilepsia · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. PMID 41248770 · J Am Acad Dermatol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. PMID 41239083 · Oncol Ther · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population. PMID 41223063 · Urol Pract · 2026-Mar The record describes a randomized trial of a decision aid for prostate cancer screening decision-making. While it is oncology-related and human, it lacks a drug-containing intervention (the intervention is a decision aid, not a pharmaceutical) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. Therefore, it does not meet the core eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Recovery After Transcervical Fibroid Ablation Versus Minimally Invasive Myomectomy for Symptomatic Uterine Fibroids: A Randomised Controlled Trial. PMID 41208417 · BJOG · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of multidisciplinary ERAS-based nursing model on postoperative recovery in patients undergoing radical resection for oral cancer. PMID 41207560 · J Stomatol Oral Maxillofac Surg · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis. PMID 41204724 · J Womens Health (Larchmt) · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension. PMID 41187976 · J Ocul Pharmacol Ther · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial. PMID 41169192 · Arthritis Rheumatol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial. PMID 41168423 · J Gastroenterol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. PMID 41151541 · Diabetes Metab J · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma. PMID 41137728 · Head Neck · 2026-Mar The study is a retrospective review comparing neoadjuvant immunotherapy to upfront surgery, not a randomized controlled trial. The phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the abstract describes a retrospective matched cohort design, not a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma. PMID 41087785 · Ann Surg Oncol · 2026-Mar This is a survey of expert opinion and practice patterns, not a report of original results from a randomized controlled trial. It does not present time-to-event efficacy data. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Artificial Intelligence 3D Augmented Reality-guided Robotic Prostatectomy Versus Cognitive MRI Intervention: Results of the Prospective Randomized RIDERS Trial. PMID 41087293 · Eur Urol · 2026-Mar The study is a randomized oncology trial with original results, but it does not meet two key inclusion criteria: 1) The intervention is not a drug (it compares surgical guidance technologies), and 2) The primary efficacy endpoint is not a time-to-event endpoint (e.g., OS, PFS, DFS) or a time-to-event analysis (e.g., Kaplan-Meier, HR); the primary endpoint was positive surgical margin (PSM) rate, a pathological outcome. While biochemical recurrence (BCR) is mentioned, it is not reported as a time-to-event analysis with Kaplan-Meier curves or hazard ratios in the provided abstract. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 2025;88:510-518. PMID 41073257 · Eur Urol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Population Pharmacokinetics and Exposure-Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. PMID 41055137 · Clin Pharmacol Ther · 2026-Mar While the record describes a study that involves data from randomized phase III trials with a drug intervention in human oncology, the analysis focuses on pharmacokinetics and exposure-response relationships. The efficacy endpoints assessed (spleen volume reduction, transfusion independence, symptom improvement) are not time-to-event endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP) and do not involve Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the required criterion for a primary or key secondary time-to-event efficacy endpoint. |
H
|
仅历史库存 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study. PMID 41004307 · Clin Exp Rheumatol · 2026-Mar The study is a subanalysis of a randomized trial in rheumatoid arthritis, not an oncology trial. The primary endpoint is a radiographic damage score (mTSS), not a time-to-event endpoint such as OS, PFS, DFS, etc. There is no evidence of Kaplan-Meier analysis or hazard ratios for time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. PMID 40977418 · Arthritis Rheumatol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |